8-K current report · filed Aug 14, 2026

Tvardi Therapeutics, Inc. (TVRD) 8-K Current Report: August 14, 2026

Item EX-99.1Item 2.02TVRD overview

Short answer

Tvardi Therapeutics, Inc. (TVRD) filed an 8-K current report with the SEC on August 14, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Fiscal quarter ended June 30, 2026 results and business highlights announced August 14, 2026.

Tvardi Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Fiscal quarter ended June 30, 2026 results and business highlights announced August 14, 2026
  • Financial details and operating updates contained in Exhibit 99.1 press release

Item EX-99.1 · Exhibit EX-99.1

  • TTI-109 healthy-volunteer data confirmed TTI-101-equivalent exposure, improved tolerability, and reductions in UC-relevant immune populations
  • UC selected as lead indication; U.S. addressable market approximately $3B versus $9B globally
  • TTI-109 UC trial targeted for 2027, contingent on IND clearance and additional funding
  • Cash, equivalents, and short-term investments declined to $15.8M from $30.8M at December 31, 2025
  • Q2 net loss $6.5M versus prior-year $4.2M net income, which included a $12.7M non-cash convertible-note gain

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Tvardi Therapeutics, Inc. 8-K filings

Get the next TVRD 8-K as it lands

Follow TVRD for push alerts, or ask the research agent what this filing means.